Fish assemblages at a deep-water sewage disposal site (DWD-106) : a final contract report

Deep-water dumpsite 106 is located over the continental slope and rise about 106 miles east of New Jersey (Fig. 1). From March 1986 to July 1992 approximately eight million wet metric tons of sewage sludge were disposed there per year (Robertson and Redford, 1992). Because of the potential impact of this dumping on deep-sea ecosystems, NOAA/NMFS contracted the Virginia Institute of Marine Science, College of William and Mary (VIMS) to make otter-trawl collections in and around DWD 106 in 1990 and 1991. Specific objectives of these collections were: 1. To sample the demersal megafauna, especially fishes; 2. To provide frozen series of dominant species of fishes and invertebrates to NMFS for subsequent heavy metal and organic analyses; 3. To provide a description of the demersal fish community structure in the area; 4. To compare these data with similar data collected from 1973 to 1978 from DWD 106 and an adjacent area to the south near Norfolk submarine canyon. This final contract report summarizes the results of these studies

Usefulness of broad-range PCR plus sequencing for the diagnosis of bacteremia due to a lung abscess

SummaryThe early detection and treatment of sepsis in patients is essential for a positive outcome. Microbiological analysis of blood cultures, as the gold standard for diagnosis, is rather slow. However, more rapid methods like PCR have become available recently and are being evaluated clinically. We present data from the monitoring of a patient with sepsis who was on anti-infective treatment. The patient was positive for Streptococcus pneumoniae by broad-range PCR and sequence analysis in a blood sample and resected lung tissue specimen, the latter embedded in paraffin, while blood culture diagnostics remained negative

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Stacking of elementary non-porous particles as XPS intensity model for supported heterogeneous catalysts: experimental assessment of validity

Mo 3/b d//Al2/b p/ XPS intensity ratios (/b R//sub Mo3d /) have been determined for a series of Al/sub 2/O/sub 3/ supported molybdenum oxides, characterized by a roughly constant Mo coverage and surface areas (/b S//sub BET/) ranging from 10 to 300 m/sup 2/ g/sup -1/. These experimental /b R//sub Mo3d / values are compared with theoretical values calculated according to three XPS intensity models. Of these three models, the stacking model the author has proposed earlier is shown to take the effect of surface area the best into account and to predict correctly the experimental values for the entire /b S//sub BET/ range. In contrast, the two other models are shown experimentally to be valid only at low or high surface area. Grain size turns out to be an important factor in XPS, in relation to diffusion-controlled impregnation which leads to concentration profiles.Anglai

Physicochemical Characterization of Supported Catalysts By Analytical Electron-microscopy, X-ray Photoelectron-spectroscopy and Ion-scattering Spectrometry

A summary of experience is reported concerning the use of AEM (Analytical Electron Microscopy), XPS (X-ray Photoelectron Spectroscopy) and ISS (Ion Scattering Spectrometry). Although the breakthroughs of XPS for catalysis research are generally known, it appears useful to attempt a critical evaluation of its application to the characterization of supported phases. The use of AEM and ISS remains up to now less widespread but since the performances of these two methods have been increased in recent years, thanks to instrumental improvements, it seems up to date to highlight the prospects offered by these techniques. It is shown how a comprehensive knowledge of the catalyst properties cited above can be achieved by an approach involving three physico-chemical tools which complement each other

[Photoelectron spectroscopy: its possibilities in application to heterogeneous catalysis. [Review]]

Francai